- €1.64bn
- -€45.51m
- CH₣112.24m
- 91
- 75
- 17
- 68
Annual balance sheet for BB Biotech AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 3,261 | 2,944 | 2,353 | 1,935 | 1,707 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.52 | 0 | — | 1.83 | 0 |
| Total Other Current Assets | |||||
| Total Current Assets | 3,963 | 3,644 | 3,053 | 2,637 | 2,407 |
| Total Assets | 3,963 | 3,644 | 3,053 | 2,637 | 2,407 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 75.6 | 361 | 367 | 314 | 121 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 75.6 | 361 | 367 | 314 | 121 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | 3,888 | 3,283 | 2,686 | 2,323 | 2,286 |
| Total Liabilities & Shareholders' Equity | 3,963 | 3,644 | 3,053 | 2,637 | 2,407 |
| Total Common Shares Outstanding |